Access All Areas Long-Acting Buprenorphine in Wales – is it time for a consistent approach?
Wales took decisive action in introducing long acting buprenorphine (LAB) to mitigate some of the challenges of delivering opioid dependence treatment during the pandemic. This conference brings together policymakers, treatment providers and patients to share their experiences and recommendations of implementing LAB as a first line treatment option and poses the question “is a national approach now needed to ensure sustained and equitable access for all?” For more details and to register for the conference, see below:
Access All Areas – Cardiff – 3 Oct 2023 – Digital invite (Welsh language).pdf
Access All Areas – Cardiff – 3 Oct 2023 – Digital invite (3).pdf
